Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Tenaya Therapeutics, Inc. (TNYA)

Tenaya Therapeutics Q3 net loss narrows to $18.9 million; cash falls to $66.8 million

Mixed Impact 3 of 5 earnings Written later

Tenaya Therapeutics reported a third-quarter 2026 net loss of $18.9 million, or $0.08 per share, down from $20.3 million, or $0.12 per share, a year earlier. The company said its cash covers planned operations into the fourth quarter of 2027, but cash has fallen from $100.5 million at December 31, 2025, and the nine-month net loss widened to $81.6 million from $70.4 million.

Key points

  • Q3 2026 collaboration revenue was $1.7 million, compared with none in Q3 2025.
  • Q3 2026 included a $666,000 impairment loss; nine-month impairment losses totaled $22.5 million.
  • Cash and cash equivalents were $66.8 million at September 30, 2026, versus $100.5 million at December 31, 2025.
  • FDA granted RMAT designation to TN-401 in September 2026; further TN-201 and TN-401 updates are planned by year end.

The filing

CompanyTenaya Therapeutics, Inc. (TNYA)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:13 PM ET
Accession number0001193125-26-447273

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.